Tuesday, December 13, 2011

Death probe for Multiple Sclerosis pill

Death probe for Multiple Sclerosis pill

One year after Novartis won FDA approval for a new type of drug to treat relapsing forms of multiple sclerosis and delay the progression of physical disabilities, the drugmaker is now investigating a death tied to its pill, which is called Gilenya. The disclosure, which was made by a Wall Street analyst, has the potential to cast a pall over a drug that has been expected to generate blockbuster sales. Specifically, this is the first death of a patient within 24 hours of taking a first dose.
Ed Silverman, Pharmalot
* * *
An example of anti-prescription hysteria.  No matter what it is -- even natural substances like peanuts -- there will be someone out there who is so severely allergic that ingesting it even once will be enough to kill them.  Those of us who would derive benefit from something should not be deprived access to medication because a small number of people had an allergic reaction.
 
I will note that a very dear friend of mine died of an allergy to aspirin.  I have heard no demands that aspirin be pulled from the market because of people like her.
 

No comments: